Development policy for the Brazilian health industry and qualification of national public laboratories

Viana, Ana Luiza d’Ávila; Silva, Hudson Pacífico da; Ibañez, Nelson; Iozzi, Fabíola Lana

doi:10.1590/0102-311x00188814

Cited by 6 publications

(1 citation statement)

References 17 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 29 The sizeable demand for medicines in the SUS has encouraged industrial domestic production of medicines through public–private partnerships. 30 …”

Section: Resource Allocationmentioning

confidence: 99%

The Brazilian health system at crossroads: progress, crisis and resilience

et al. 2018

View full text Add to dashboard Cite

The Unified Health System (Sistema Único de Saúde (SUS)) has enabled substantial progress towards Universal Health Coverage (UHC) in Brazil. However, structural weakness, economic and political crises and austerity policies that have capped public expenditure growth are threatening its sustainability and outcomes. This paper analyses the Brazilian health system progress since 2000 and the current and potential effects of the coalescing economic and political crises and the subsequent austerity policies. We use literature review, policy analysis and secondary data from governmental sources in 2000–2017 to examine changes in political and economic context, health financing, health resources and healthcare service coverage in SUS. We find that, despite a favourable context, which enabled expansion of UHC from 2003 to 2014, structural problems persist in SUS, including gaps in organisation and governance, low public funding and suboptimal resource allocation. Consequently, large regional disparities exist in access to healthcare services and health outcomes, with poorer regions and lower socioeconomic population groups disadvantaged the most. These structural problems and disparities will likely worsen with the austerity measures introduced by the current government, and risk reversing the achievements of SUS in improving population health outcomes. The speed at which adverse effects of the current and political crises are manifested in the Brazilian health system underscores the importance of enhancing health system resilience to counteract external shocks (such as economic and political crises) and internal shocks (such as sector-specific austerity policies and rapid ageing leading to rise in disease burden) to protect hard-achieved progress towards UHC.

show abstract

“… 29 The sizeable demand for medicines in the SUS has encouraged industrial domestic production of medicines through public–private partnerships. 30 …”

Section: Resource Allocationmentioning

confidence: 99%

The Brazilian health system at crossroads: progress, crisis and resilience

et al. 2018

View full text Add to dashboard Cite

show abstract

A Consortium in Times of Crisis: Producing Brazilian Sofosbuvir? (2014–2017)

Cassier

Corrêa

2018

Health Innovation and Social Justice in Brazil

View full text Add to dashboard Cite

Produção pública de medicamentos no Brasil no contexto da pandemia da COVID-19

Neto¹,

Cunha²

2020

Rev. G&S

View full text Add to dashboard Cite

No Brasil, o Sistema Único de Saúde foi instituído nas bases da Constituição Federal de 1988, que estabeleceu, dentre outros campos de atuação, a sua participação na produção de medicamentos e na promoção do desenvolvimento científico e tecnológico e a inovação em saúde. Este ensaio discute a produção pública de medicamentos no âmbito dos laboratórios oficiais e seus desafios no contexto da pandemia de COVID-19, utilizando-se como base os medicamentos do estudo Solidarity. O Brasil conta com 20 laboratórios oficiais que juntos possuem 289 medicamentos aprovados, compostos por 169 fármacos, em diferentes apresentações, além de 86 Parcerias para o Desenvolvimento Produtivo vigentes que envolvem o desenvolvimento e transferência de tecnologias de outros 55 medicamentos. Nos últimos anos, diversas políticas desenvolvidas no Brasil promoveram o desenvolvimento e a produção de medicamentos estratégicos para a população, reduzindo a dependência produtiva e tecnológica e contribuindo para a diminuição da vulnerabilidade do SUS. Contudo, desafios como a deficiência de infraestrutura e de competências técnicas e gerenciais dos laboratórios públicos, dependência externa de insumos farmacêuticos e políticas recentes de austeridade fiscal, fragilizam o País para o enfrentamento da pandemia.

show abstract

Development policy for the Brazilian health industry and qualification of national public laboratories

Abstract: A política de desenvolvimento produtivo da saúde e a capacitação dos laboratórios públicos nacionais La política de desarrollo productivo en salud en Brasil y la cualificación de los laboratorios públicos nacionales

Cited by 6 publications

References 17 publications

The Brazilian health system at crossroads: progress, crisis and resilience

The Brazilian health system at crossroads: progress, crisis and resilience

A Consortium in Times of Crisis: Producing Brazilian Sofosbuvir? (2014–2017)

Produção pública de medicamentos no Brasil no contexto da pandemia da COVID-19

Contact Info

Product

Resources

About